These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36574181)

  • 1. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.
    Fröhlich F; Micheroli R; Hebeisen M; Kissling S; Bürki K; Exer P; Bräm R; Niedermann K; Möller B; Nissen MJ; Kyburz D; Andor M; Distler O; Scherer A; Ciurea A
    Clin Rheumatol; 2023 May; 42(5):1267-1274. PubMed ID: 36574181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
    Ciurea A; Götschi A; Bräm R; Bürki K; Exer P; Andor M; Nissen MJ; Möller B; Hügle T; Rubbert-Roth A; Kyburz D; Distler O; Scherer A; Micheroli R
    RMD Open; 2023 Dec; 9(4):. PubMed ID: 38053462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
    Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
    Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
    Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
    Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To be or not to B27 positive: implications for the phenotypes of axial spondyloarthritis outcomes. Data from a large multiracial cohort from the Brazilian Registry of Spondyloarthritis.
    Resende GG; Saad CGS; Marques CDL; Ribeiro SLE; de Oliveira Gavi MBR; Yazbek MA; de Oliveira Marinho A; de Cássia Menin R; Ochtrop MLG; Soares AM; Cavalcanti NG; Carneiro JN; Werner de Castro GR; Fernandes JMC; da Cruz Ribeiro E Souza E; de Menezes Alvarenga CQ; de Abreu Vieira RMR; Machado NP; Ximenes AC; Gazzeta MO; de Albuquerque CP; Skare TL; Waldemar Keiserman M; Kohem CL; Benacon GS; Rocha VFS; da Cruz Lage R; Malheiro OB; Golebiovski RTM; Oliveira TL; Duque RH; Londe AC; de Medeiros Pinheiro M; Sampaio-Barros PD
    Adv Rheumatol; 2024 Apr; 64(1):33. PubMed ID: 38671475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore.
    Hong C; Kwan YH; Leung YY; Lui NL; Fong W
    Int J Rheum Dis; 2019 Aug; 22(8):1506-1511. PubMed ID: 31090201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort.
    Ciurea A; Kissling S; Bürki K; Baraliakos X; de Hooge M; Hebeisen M; Papagiannoulis E; Exer P; Bräm R; Nissen MJ; Möller B; Kyburz D; Andor M; Distler O; Scherer A; Micheroli R
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35110365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
    Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA.
    Arévalo M; López-Medina C; Moreno Martinez-Losa M; Moltó A; Font P; Collantes-Estevez E; Gratacós J
    Joint Bone Spine; 2020 Oct; 87(5):445-448. PubMed ID: 32251735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
    Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
    Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry.
    Bodur H; Yurdakul FG; Ataman S; Cay HF; Gurer G; Capkin E; Sezer İ; Duruoz MT; Melikoglu MA; Rezvani A; Yagci I; Gogus F; Kamanli A; Akgul O; Cevik R
    Clin Rheumatol; 2022 Jul; 41(7):2053-2063. PubMed ID: 35353263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter.
    Li Z; van der Linden SM; Khan MA; Baumberger H; Zandwijk HV; Khan MK; Villiger PM; Brown MA
    RMD Open; 2022 May; 8(1):. PubMed ID: 35523521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10-Year Results From the German Spondyloarthritis Inception Cohort.
    Torgutalp M; Rios Rodriguez V; Proft F; Protopopov M; Verba M; Rademacher J; Haibel H; Sieper J; Rudwaleit M; Poddubnyy D
    Arthritis Rheumatol; 2022 Sep; 74(9):1515-1523. PubMed ID: 35437900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence-Based Data Analyses of a National Multicenter Prospective Registry.
    Fernández-Carballido C; Sanchez-Piedra C; Valls R; Garg K; Sánchez-Alonso F; Artigas L; Mas JM; Jovaní V; Manrique S; Campos C; Freire M; Martínez-González O; Castrejón I; Perella C; Coma M; van der Horst-Bruinsma IE
    Arthritis Care Res (Hoboken); 2023 Jan; 75(1):115-124. PubMed ID: 36278846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts.
    Ez-Zaitouni Z; Hilkens A; Gossec L; Berg IJ; Landewé R; Ramonda R; Dougados M; van der Heijde D; van Gaalen F
    Arthritis Res Ther; 2017 May; 19(1):118. PubMed ID: 28569222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.